{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:24:17Z","timestamp":1787502257898,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Molecular differences in colorectal cancer (CRC) are associated with the metastatic route. Patient survival is mainly driven by metastatic spread thus it is imperative to understand its key drivers to develop biomarkers for risk stratification, follow-up protocols and personalized therapy. Thus, this study aimed to identify genes associated with the metastatic route in CRC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and methods<\/jats:title>\n                    <jats:p>\n                      CRC patients resected at our clinic from 2005 to 2014 and with a minimum 5-year follow-up were included in this analysis and grouped into CRC with hepatic (HEP), peritoneal (PER) or without distant metastases (M0), and HEP\/PER. Firstly, tumor RNA of 6 patients each was isolated by microdissection from formalin-fixed paraffin-embedded specimens and analyzed by a NanoString analysis. Subsequently, these results were validated with immunohistochemistry and correlated to clinicopathological parameters in a larger collective of CRC patients (HEP\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200951, PER\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200944, M0\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200947, HEP\/PER\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200928).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Compared to M0, HEP tumors showed 20 differentially expressed genes associated with epithelial-mesenchymal transition (EMT) and angiogenesis. Compared to M0, PER tumors had 18 differentially expressed genes. The finding of different gene signatures was supported by the multidimensional principal component clustering analysis. Tumor perforation did not influence the metastatic route. CIB1 was homogenously and significantly overexpressed in HEP compared to M0 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), but not in PER. Furthermore, immunohistochemical validation demonstrated that the mean CIB1 expression in HEP was 80% higher than in M0 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Gene expression analysis revealed that CIB1 is significantly overexpressed in CRC leading to liver metastases compared to M0 and PER. Thus, the present results suggest that CIB1 may play a crucial role for hematogenous spread to the liver but not for peritoneal carcinomatosis. Consequently, CIB1 seems to be a promising prognostic marker and a potential tool for future targeted therapies as well as early diagnostics and follow-up.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-021-08927-w","type":"journal-article","created":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T19:03:08Z","timestamp":1637262188000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Expression of CIB1 correlates with colorectal liver metastases but not with peritoneal carcinomatosis"],"prefix":"10.1186","volume":"21","author":[{"given":"Sven","family":"Jacob","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"B\u00f6sch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus B.","family":"Schoenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Pretzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Lampert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren","family":"Haoyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard W.","family":"Renz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies","family":"Michl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Kumbrink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kirchner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin K.","family":"Angele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,18]]},"reference":[{"issue":"5","key":"8927_CR1","first-page":"1801","volume":"24","author":"A Sakin","year":"2019","unstructured":"Sakin A, Sahin S, Atci MM, Yasar N, Geredeli C, Aribal S, et al. Factors affecting survival in patients with isolated liver-metastatic colorectal cancer treated with local ablative or surgical treatments for liver metastasis. J BUON. 2019;24(5):1801\u20138.","journal-title":"J BUON"},{"issue":"4","key":"8927_CR2","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1136\/gutjnl-2015-310912","volume":"66","author":"M Arnold","year":"2017","unstructured":"Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683\u201391. https:\/\/doi.org\/10.1136\/gutjnl-2015-310912.","journal-title":"Gut."},{"issue":"6","key":"8927_CR3","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1097\/DCR.0000000000001367","volume":"62","author":"G Baguena","year":"2019","unstructured":"Baguena G, Pellino G, Frasson M, Rosello S, Cervantes A, Garcia-Granero A, et al. Prognostic impact of pT stage and peritoneal invasion in locally advanced Colon Cancer. Dis Colon Rectum. 2019;62(6):684\u201393. https:\/\/doi.org\/10.1097\/DCR.0000000000001367.","journal-title":"Dis Colon Rectum"},{"issue":"1","key":"8927_CR4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/1878-0261.12018","volume":"11","author":"DV Tauriello","year":"2017","unstructured":"Tauriello DV, Calon A, Lonardo E, Batlle E. Determinants of metastatic competency in colorectal cancer. Mol Oncol. 2017;11(1):97\u2013119. https:\/\/doi.org\/10.1002\/1878-0261.12018.","journal-title":"Mol Oncol"},{"issue":"2","key":"8927_CR5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69\u201390. https:\/\/doi.org\/10.3322\/caac.20107.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"8927_CR6","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s10585-015-9719-0","volume":"32","author":"LG van der Geest","year":"2015","unstructured":"van der Geest LG, Lam-Boer J, Koopman M, Verhoef C, Elferink MA, de Wilt JH. Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases. Clin Exp Metastasis. 2015;32(5):457\u201365. https:\/\/doi.org\/10.1007\/s10585-015-9719-0.","journal-title":"Clin Exp Metastasis"},{"key":"8927_CR7","doi-asserted-by":"publisher","first-page":"7407190","DOI":"10.1155\/2019\/7407190","volume":"2019","author":"E Pretzsch","year":"2019","unstructured":"Pretzsch E, Bosch F, Neumann J, Ganschow P, Bazhin A, Guba M, et al. Mechanisms of metastasis in colorectal Cancer and metastatic organotropism: Hematogenous versus peritoneal spread. J Oncol. 2019;2019:7407190\u201313. https:\/\/doi.org\/10.1155\/2019\/7407190.","journal-title":"J Oncol"},{"issue":"9927","key":"8927_CR8","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1016\/S0140-6736(13)61649-9","volume":"383","author":"H Brenner","year":"2014","unstructured":"Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014;383(9927):1490\u2013502. https:\/\/doi.org\/10.1016\/S0140-6736(13)61649-9.","journal-title":"Lancet."},{"issue":"8","key":"8927_CR9","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.prp.2015.05.010","volume":"211","author":"H Cao","year":"2015","unstructured":"Cao H, Xu E, Liu H, Wan L, Lai M. Epithelial-mesenchymal transition in colorectal cancer metastasis: a system review. Pathol Res Pract. 2015;211(8):557\u201369. https:\/\/doi.org\/10.1016\/j.prp.2015.05.010.","journal-title":"Pathol Res Pract"},{"issue":"6","key":"8927_CR10","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1053\/j.gastro.2007.09.008","volume":"133","author":"M Fukata","year":"2007","unstructured":"Fukata M, Chen A, Vamadevan AS, Cohen J, Breglio K, Krishnareddy S, et al. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology. 2007;133(6):1869\u201381. https:\/\/doi.org\/10.1053\/j.gastro.2007.09.008.","journal-title":"Gastroenterology."},{"issue":"3","key":"8927_CR11","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1242\/dmm.027441","volume":"10","author":"AM Strubberg","year":"2017","unstructured":"Strubberg AM, Madison BB. MicroRNAs in the etiology of colorectal cancer: pathways and clinical implications. Dis Model Mech. 2017;10(3):197\u2013214. https:\/\/doi.org\/10.1242\/dmm.027441.","journal-title":"Dis Model Mech"},{"issue":"4","key":"8927_CR12","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.bbrc.2013.12.012","volume":"445","author":"R Arroyo","year":"2014","unstructured":"Arroyo R, Duran-Frigola M, Berenguer C, Soler-Lopez M, Aloy P. Charting the molecular links between driver and susceptibility genes in colorectal cancer. Biochem Biophys Res Commun. 2014;445(4):734\u20138. https:\/\/doi.org\/10.1016\/j.bbrc.2013.12.012.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"8927_CR13","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1158\/1078-0432.CCR-12-1703","volume":"19","author":"H Siemens","year":"2013","unstructured":"Siemens H, Neumann J, Jackstadt R, Mansmann U, Horst D, Kirchner T, et al. Detection of miR-34a promoter methylation in combination with elevated expression of c-met and \u03b2-catenin predicts distant metastasis of colon cancer. Clin Cancer Res. 2013;19(3):710\u201320. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-1703.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"8927_CR14","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/his.13975","volume":"76","author":"ID Nagtegaal","year":"2020","unstructured":"Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182\u20138. https:\/\/doi.org\/10.1111\/his.13975.","journal-title":"Histopathology."},{"issue":"4","key":"8927_CR15","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00428-017-2276-y","volume":"472","author":"L Bertero","year":"2018","unstructured":"Bertero L, Massa F, Metovic J, Zanetti R, Castellano I, Ricardi U, et al. Eighth edition of the UICC classification of malignant Tumours: an overview of the changes in the pathological TNM classification criteria-what has changed and why? Virchows Arch. 2018;472(4):519\u201331. https:\/\/doi.org\/10.1007\/s00428-017-2276-y.","journal-title":"Virchows Arch"},{"issue":"4","key":"8927_CR16","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1159\/000481873","volume":"43","author":"X Wang","year":"2017","unstructured":"Wang X, Peng X, Zhang X, Xu H, Lu C, Liu L, et al. The emerging roles of CIB1 in Cancer. Cell Physiol Biochem. 2017;43(4):1413\u201324. https:\/\/doi.org\/10.1159\/000481873.","journal-title":"Cell Physiol Biochem"},{"issue":"Suppl 1","key":"8927_CR17","doi-asserted-by":"publisher","first-page":"s123","DOI":"10.1007\/s10151-004-0131-z","volume":"8","author":"VN Papadopoulos","year":"2004","unstructured":"Papadopoulos VN, Michalopoulos A, Netta S, Basdanis G, Paramythiotis D, Zatagias A, et al. Prognostic significance of mucinous component in colorectal carcinoma. Techniques Coloproctol. 2004;8(Suppl 1):s123\u20135. https:\/\/doi.org\/10.1007\/s10151-004-0131-z.","journal-title":"Techniques Coloproctol"},{"issue":"15","key":"8927_CR18","doi-asserted-by":"publisher","first-page":"e658","DOI":"10.1097\/MD.0000000000000658","volume":"94","author":"JS Park","year":"2015","unstructured":"Park JS, Huh JW, Park YA, Cho YB, Yun SH, Kim HC, et al. Prognostic comparison between mucinous and nonmucinous adenocarcinoma in colorectal cancer. Medicine. 2015;94(15):e658. https:\/\/doi.org\/10.1097\/MD.0000000000000658.","journal-title":"Medicine."},{"key":"8927_CR19","doi-asserted-by":"crossref","unstructured":"Sundar R, Liu DH, Hutchins GG, Slaney HL, Silva AN, Oosting J, et al. Spatial profiling of gastric cancer patient-matched primary and locoregional metastases reveals principles of tumour dissemination. Gut. 2020.","DOI":"10.1136\/gutjnl-2020-320805"},{"issue":"1","key":"8927_CR20","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12885-020-6608-y","volume":"20","author":"RS Dettogni","year":"2020","unstructured":"Dettogni RS, Stur E, Laus AC, da Costa Vieira RA, Marques MMC, Santana IVV, et al. Potential biomarkers of ductal carcinoma in situ progression. BMC Cancer. 2020;20(1):119. https:\/\/doi.org\/10.1186\/s12885-020-6608-y.","journal-title":"BMC Cancer"},{"issue":"8","key":"8927_CR21","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1096\/fj.201500073R","volume":"30","author":"TM Leisner","year":"2016","unstructured":"Leisner TM, Freeman TC, Black JL, Parise LV. CIB1: a small protein with big ambitions. FASEB J. 2016;30(8):2640\u201350. https:\/\/doi.org\/10.1096\/fj.201500073R.","journal-title":"FASEB J"},{"issue":"4","key":"8927_CR22","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s12038-011-9101-6","volume":"36","author":"T Junrong","year":"2011","unstructured":"Junrong T, Huancheng Z, Feng H, Yi G, Xiaoqin Y, Zhengmao L, et al. Proteomic identification of CIB1 as a potential diagnostic factor in hepatocellular carcinoma. J Biosci. 2011;36(4):659\u201368. https:\/\/doi.org\/10.1007\/s12038-011-9101-6.","journal-title":"J Biosci"},{"issue":"9","key":"8927_CR23","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/onc.2013.43","volume":"33","author":"M Armacki","year":"2014","unstructured":"Armacki M, Joodi G, Nimmagadda SC, de Kimpe L, Pusapati GV, Vandoninck S, et al. A novel splice variant of calcium and integrin-binding protein 1 mediates protein kinase D2-stimulated tumour growth by regulating angiogenesis. Oncogene. 2014;33(9):1167\u201380. https:\/\/doi.org\/10.1038\/onc.2013.43.","journal-title":"Oncogene."},{"issue":"Suppl 3","key":"8927_CR24","doi-asserted-by":"publisher","first-page":"S459","DOI":"10.1245\/s10434-014-3574-0","volume":"21","author":"Y Nagayoshi","year":"2014","unstructured":"Nagayoshi Y, Nakamura M, Matsuoka K, Ohtsuka T, Mori Y, Kono H, et al. Profiling of autoantibodies in sera of pancreatic cancer patients. Ann Surg Oncol. 2014;21(Suppl 3):S459\u201365. https:\/\/doi.org\/10.1245\/s10434-014-3574-0.","journal-title":"Ann Surg Oncol"},{"issue":"42","key":"8927_CR25","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.1038\/sj.onc.1203845","volume":"19","author":"U Holtrich","year":"2000","unstructured":"Holtrich U, Wolf G, Yuan J, Bereiter-Hahn J, Karn T, Weiler M, et al. Adhesion induced expression of the serine\/threonine kinase Fnk in human macrophages. Oncogene. 2000;19(42):4832\u20139. https:\/\/doi.org\/10.1038\/sj.onc.1203845.","journal-title":"Oncogene."},{"issue":"1","key":"8927_CR26","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1074\/jbc.M109.068395","volume":"285","author":"KE Jarman","year":"2010","unstructured":"Jarman KE, Moretti PA, Zebol JR, Pitson SM. Translocation of sphingosine kinase 1 to the plasma membrane is mediated by calcium- and integrin-binding protein 1. J Biol Chem. 2010;285(1):483\u201392. https:\/\/doi.org\/10.1074\/jbc.M109.068395.","journal-title":"J Biol Chem"},{"issue":"18","key":"8927_CR27","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1038\/onc.2016.428","volume":"36","author":"W Zhu","year":"2017","unstructured":"Zhu W, Gliddon BL, Jarman KE, Moretti PAB, Tin T, Parise LV, et al. CIB1 contributes to oncogenic signalling by Ras via modulating the subcellular localisation of sphingosine kinase 1. Oncogene. 2017;36(18):2619\u201327. https:\/\/doi.org\/10.1038\/onc.2016.428.","journal-title":"Oncogene."},{"issue":"11","key":"8927_CR28","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/nrc3106","volume":"11","author":"Y Pylayeva-Gupta","year":"2011","unstructured":"Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011;11(11):761\u201374. https:\/\/doi.org\/10.1038\/nrc3106.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"8927_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","volume":"51","author":"FR Greten","year":"2019","unstructured":"Greten FR, Grivennikov SI. Inflammation and Cancer: triggers, mechanisms, and consequences. Immunity. 2019;51(1):27\u201341. https:\/\/doi.org\/10.1016\/j.immuni.2019.06.025.","journal-title":"Immunity."},{"issue":"18","key":"8927_CR30","first-page":"4181","volume":"21","author":"L Zhang","year":"2017","unstructured":"Zhang L, Tang F, Cai LP, Wang HL, Wang Z. Research on the correlation of urine calcium integrin binding protein-1 and pro-BNP with ischemic heart failure. Eur Rev Med Pharmacol Sci. 2017;21(18):4181\u20135.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"8927_CR31","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.2147\/DDDT.S83288","volume":"9","author":"Y Gao","year":"2015","unstructured":"Gao Y, Gao F, Chen K, Tian ML, Zhao DL. Sphingosine kinase 1 as an anticancer therapeutic target. Drug Des Devel Ther. 2015;9:3239\u201345. https:\/\/doi.org\/10.2147\/DDDT.S83288.","journal-title":"Drug Des Devel Ther"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08927-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08927-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08927-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T19:05:03Z","timestamp":1637262303000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08927-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,18]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8927"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08927-w","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,18]]},"assertion":[{"value":"10 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was carried out according to the recommendations of the ethics committee of the Medical Faculty of the Ludwig-Maximilians-University Munich, Germany. The current study has been performed in a retro-spective manner in a cohort of patients diagnosed and treated according to national guide-lines. In addition, the data set as well as the specimens were irreversibly anonymized prior to inclusion in the study. Hence, under the circumstances aforementioned, neither a written consent nor a project specific approval by the ethic committee was necessary.The study was performed according to the standards set in the declaration of Helsinki 1975. All researchers were blinded from patient data during experimental analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This study used tumor tissue that had initially been collected for histo-pathological diagnostics. At the time, the tissue was examined for the current study all diagnostic procedures had already been fully completed and the tissue used was thus classified as left-over material. All patient data were fully anonymized. As per declaration of our ethics committee (Ludwig-Maximilians-University Medical School (Munich, Germany)) no written informed consent of the participants is needed given the circumstances described above.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JN is senior editorial board member of BMC Cancer. All other authors have no related conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1243"}}